Literature DB >> 8972687

Methylcholanthrene-induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression.

A M Engel1, I M Svane, S Mouritsen, J Rygaard, J Clausen, O Werdelin.   

Abstract

In order to study the role of the T-cell-mediated immune defense in tumor development, a total of 93 sarcomas were induced using different doses (8 micrograms (0.1%), 40 micrograms (0.5%) and 400 micrograms (5%)) of 3-methylcholanthrene in athymic nude Balb/c mice and phenotypically normal immunocompetent Balb/c mice. A shorter tumor induction time and a higher tumor incidence after treatment with low doses of methylcholanthrene were seen in nude mice than in immunocompetent mice, indicating that they have a lower resistance to the carcinogen. Contrary to expectations we found that the MHC class I expression of tumors from nude mice was lower than that of tumors from normal mice. Higher surface expression of MHC class I was demonstrated on high dose tumors from normal mice than on low dose tumors from normal mice. The cellular composition of the individual tumors raised in nude mice was more heterogeneous with respect to MHC class I expression. Since the mice differ genetically only with respect to the nu gene, these results indicate that a lack of T-cell-mediated defense mechanisms may confer upon the bearer a lower resistance to 3-methylcholanthrene and a different MHC profile of the ensuing tumor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8972687     DOI: 10.1111/j.1699-0463.1996.tb04923.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  11 in total

1.  CD8+ T cells are crucial for the ability of congenic normal mice to reject highly immunogenic sarcomas induced in nude mice with 3-methylcholanthrene.

Authors:  M Boesen; I M Svane; A M Engel; J Rygaard; A R Thomsen; O Werdelin
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  Revisiting cancer immunoediting by understanding cancer immune complexity.

Authors:  Masoud H Manjili
Journal:  J Pathol       Date:  2011-05       Impact factor: 7.996

Review 3.  The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice.

Authors:  I M Svane; M Boesen; A M Engel
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

4.  Global gene expression profiling in interleukin-12-induced activation of CD8(+) cytotoxic T lymphocytes against mouse mammary Carcinoma.

Authors:  Shanjin Cao; Zhaoying Xiang; Xiaojing Ma
Journal:  Cell Mol Immunol       Date:  2004-10       Impact factor: 11.530

Review 5.  Cancer immunoediting from immune surveillance to immune escape.

Authors:  Ryungsa Kim; Manabu Emi; Kazuaki Tanabe
Journal:  Immunology       Date:  2007-03-26       Impact factor: 7.397

Review 6.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  Immune selection in murine tumors. A study of MCA induced sarcomas in normal and immunodeficient mice.

Authors:  A M Engel; I M Svane; J Rygaard; O Werdelin
Journal:  Folia Microbiol (Praha)       Date:  1998       Impact factor: 2.099

8.  A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability.

Authors:  Shingo Iwami; Hiroshi Haeno; Franziska Michor
Journal:  PLoS Comput Biol       Date:  2012-02-16       Impact factor: 4.475

Review 9.  The Janus Face of Death Receptor Signaling during Tumor Immunoediting.

Authors:  Eimear O' Reilly; Andrea Tirincsi; Susan E Logue; Eva Szegezdi
Journal:  Front Immunol       Date:  2016-10-31       Impact factor: 7.561

Review 10.  Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.

Authors:  John Reiser; Arnob Banerjee
Journal:  J Immunol Res       Date:  2016-05-22       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.